MedTrace Logo

Mycophenolate Mofetil for the Prophylaxis of Graft-versus-host Disease in High Risk Allogeneic Stem Cell Transplantation

NCT00563589 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2010-07-07

No results posted yet for this study

Summary

There is a significant (50-80%) risk of acute graft-versus-host disease(GVHD) and early mortality (30%) associated with high risk stem cell transplantation (SCT) such as that from a matched unrelated donor or HLA-mismatch sibling. Mycophenolate mofetil (MMF) has been shown to be an effective and safe immunosuppressant in the prevention and treatment of rejection after solid organ transplantation. Its role in acute GVHD prophylaxis in high risk SCT will be investigated in this clinical trial.

Conditions

  • Graft vs Host Disease
  • Hematopoietic Stem Cell Transplantation

Interventions

DRUG

mycophenolate mofetil, methotrexate, cyclosporin

DRUG

Methotrexate and cyclosporin

Sponsors & Collaborators

  • Hoffmann-La Roche

    collaborator INDUSTRY

  • Hospital Authority, Hong Kong

    lead OTHER_GOV

Principal Investigators

  • Lawrence SY Ma, Dr · Department of Medicine/ Haematology and Oncology, Queen Mary Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-08-31
Completion
2008-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00563589 on ClinicalTrials.gov